Results 1 to 10 of about 8,581 (194)

265 Self-reported rates of psilocybin use in North Florida, 2012 to present [PDF]

Journal of Clinical and Translational Science
Objectives/Goals: Mainstream interest in psilocybin (“shrooms”) has grown over the past several years as two US states have “legalized” psilocybin and clinical trials are underway for use in multiple mental health conditions.
Tamara Millay, Monica Bhargavi Kodali, Linda Cottler   +2 more
doaj   +2 more sources

Single-dose psilocybin promotes cell-type-specific changes of neurons in the orbitofrontal cortex [PDF]

Neurotherapeutics
Recent clinical breakthroughs hold great promise for the application of psilocybin in the treatments of psychological disorders, such as depression, addiction, and obsessive-compulsive disorder.
Ziran Huang, Xiaoyan Wei, Yihui Wang, Jing Tian, Jihui Dong, Bo Liang, Lin Lu, Wen Zhang   +7 more
doaj   +2 more sources

Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins [PDF]

Frontiers in Psychiatry
BackgroundObsessive-Compulsive Disorder (OCD) can present significant challenges to individuals mental health, characterized by intrusive thoughts and repetitive maladaptive behaviors.
Sivert Drange, Sivert Drange, Jacob Cohen, Jacob Cohen, Jacob Cohen, Jacob Cohen, Sys Stybe Johansen, Ben Dunkley, Mikael Palner, Mikael Palner, Mikael Palner   +10 more
doaj   +2 more sources

Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in Gymnopilus dilepis Mushroom via Amino Acid Metabolism Pathways

Journal of Fungi, 2022
As a potential medicine for the treatment of depression, psilocybin has gradually attracted attention. To elucidate the molecular mechanism regulating psilocybin synthesis in Gymnopilus dilepis, ultra-performance liquid chromatography (UPLC) was used to ...
Sen Yao, Chuanzheng Wei, Hui Lin, Peng Zhang, Yuanyuan Liu, Youjin Deng, Qianhui Huang, Baogui Xie   +7 more
doaj   +1 more source

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey

Frontiers in Psychiatry, 2023
IntroductionThe classic psychedelic psilocybin, found in some mushroom species, has received renewed interest in clinical research, showing potential mental health benefits in preliminary trials.
Sandeep M. Nayak, Sandeep M. Nayak, Hillary Jackson, Hillary Jackson, Nathan D. Sepeda, Nathan D. Sepeda, Nathan D. Sepeda, David S. Mathai, David S. Mathai, Sara So, Sara So, Abigail Yaffe, Abigail Yaffe, Hadi Zaki, Hadi Zaki, Trey J. Brasher, Matthew X. Lowe, Del R. P. Jolly, Frederick S. Barrett, Frederick S. Barrett, Frederick S. Barrett, Frederick S. Barrett, Roland R. Griffiths, Roland R. Griffiths, Roland R. Griffiths, Justin C. Strickland, Justin C. Strickland, Matthew W. Johnson, Heather Jackson, Albert Garcia-Romeu, Albert Garcia-Romeu   +30 more
doaj   +1 more source

Association of Psilocybin Use in Adolescents with Major Depressive Episode

European Psychiatry, 2022
Introduction Psilocybin is a psychedelic drug found in mushrooms, often referred to as magic mushrooms due to its visual and auditory hallucinations effects upon ingestion.
K. Shah, C. Trivedi, D. Kamrai, M. Akbar, W. Tankersley   +4 more
doaj   +1 more source

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls

Scientific Reports, 2022
Psilocybin microdosing involves repeated self-administration of mushrooms containing psilocybin at doses small enough to not impact regular functioning. Microdose practices are diverse and include combining psilocybin with substances such as lion’s mane ...
Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow, Kalin Harvey, Paul Stamets, Eesmyal Santos-Brault, Kim P. C. Kuypers, Zach Walsh   +7 more
doaj   +1 more source

Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats

Translational Psychiatry, 2023
Alcohol Use Disorder (AUD) adversely affects the lives of millions of people, but still lacks effective treatment options. Recent advancements in psychedelic research suggest psilocybin to be potentially efficacious for AUD. However, major knowledge gaps
Jonathan R. Reinwald, Christian N. Schmitz, Ivan Skorodumov, Martin Kuchar, Wolfgang Weber-Fahr, Rainer Spanagel, Marcus W. Meinhardt   +6 more
doaj   +1 more source

Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial

BJPsych Open, 2023
Background Randomised controlled trials (RCTs) of psilocybin have reported large antidepressant effects in adults with major depressive disorder and treatment-resistant depression (TRD).
Muhammad Ishrat Husain, Daniel M. Blumberger, David J. Castle, Nicole Ledwos, Elise Fellows, Brett D. M. Jones, Abigail Ortiz, Stefan Kloiber, Wei Wang, Joshua D. Rosenblat, Benoit H. Mulsant   +10 more
doaj   +1 more source

Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder

Translational Psychiatry, 2023
Preliminary clinical findings, supported by preclinical studies employing behavioral paradigms such as marble burying, suggest that psilocybin may be effective in treating obsessive-compulsive disorder.
Sandeep Singh, Alexander Botvinnik, Orr Shahar, Gilly Wolf, Corel Yakobi, Michal Saban, Adham Salama, Amit Lotan, Bernard Lerer, Tzuri Lifschytz   +9 more
doaj   +1 more source